Screener
Cytokinetics CYTK Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $255,271 | $122,518 |
| Short-term investments | 910,415 | 759,703 |
| Accounts receivable, net | 24,432 | 17,764 |
| Inventories | 380 | — |
| Prepaid expenses and other current assets | 17,989 | 16,990 |
| Total current assets | 1,208,487 | 916,975 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's short-term investments?
- Cytokinetics (CYTK) reported short-term investments of $910.42M in Q2 2026.
- How has Cytokinetics's short-term investments changed year-over-year?
- Cytokinetics's short-term investments increased by 16.2% year-over-year, from $783.2M to $910.42M.
- What is the long-term trend for Cytokinetics's short-term investments?
- Over 5 years (2020 to 2025), Cytokinetics's short-term investments has grown at a 14.8% compound annual growth rate (CAGR), from $381.08M to $759.7M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Cytokinetics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude